Eli Lilly and Company lands in Toronto days after Kisunla approval

Eli Lilly and Company's Gulfstream G500, tail number N308EL, touched down at Toronto Pearson International Airport early on May 7, 2026, after a brisk 2-hour-28-minute flight from Centennial Airport near Denver. Departing late the previous evening, the aircraft cruised at a maximum altitude of 45,025 feet and peaked at 598 knots ground speed, slicing through the night sky en route to Canada's largest city.

The timing raises eyebrows: just three days earlier, on May 4, Lilly Canada announced that Health Canada had authorized Kisunla (donanemab), the company's once-monthly infusion for early symptomatic Alzheimer's disease, marking the second such drug approved in the country. As covered by CNW Group, this milestone comes after over 35 years of research investment, positioning Eli Lilly and Company to expand its neuroscience footprint northward amid growing demand for innovative therapies.

This Toronto jaunt fits a pattern of North American shuttling for the Indianapolis-based firm, whose fleet often hops between U.S. hubs like Chicago and Minneapolis—recurring destinations tied to regulatory and partner meetings. On May 6 alone, multiple flights crisscrossed from Kansas City to Denver, suggesting executives converging before the cross-border push, a wry reminder that even pharma jets don't escape the pull of fresh approvals.